Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 1/20 | 0.58 |
| ▸ | DRD4 | P21917 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12222581 | 0.86 | NPC1 (0.58) | NPC1MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL12222580 | 0.84 | NPC1 (0.58) | NPC1MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL27615799 | 0.82 | MEN1 (0.64) | MEN1KMT2AKDM4EALDH1A1TSHR | |
| SCHEMBL14019999 | 0.81 | KDM4E (0.55) | NPC1MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL21538245 | 0.80 | KDM4E (0.67) | NPC1MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL18182089 | 0.80 | KDM4E (0.67) | NPC1MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL9426828 | 0.80 | MTNR1B (0.64) | NPC1MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL9830022 | 0.80 | KDM4E (0.68) | NPC1MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL10071056 | 0.79 | SIGMAR1 (0.62) | MEN1KMT2AALDH1A1DRD2DRD4 | |
| SCHEMBL4395358 | 0.79 | DRD4 (0.51) | MEN1KMT2AKDM4EALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9643960-B2 | Procaspase activating compounds | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-05-09 | — | — | US | disclosed |
| US-9643960-B2 | Procaspase activating compounds | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-05-09 | — | — | US | disclosed |
| EP-2393794-B1 | DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS | UNIV ILLINOIS (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20150344452-A1 | PROCASPASE ACTIVATING COMPOUNDS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344452-A1 | PROCASPASE ACTIVATING COMPOUNDS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-12-03 | — | — | US | disclosed |
| US-9102661-B2 | Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs | THE BOARD OF TRUSTEES OF THE UNIVERSITY ILLINOIS (US) | 2015-08-11 | — | — | US | disclosed |
| US-9102661-B2 | Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs | THE BOARD OF TRUSTEES OF THE UNIVERSITY ILLINOIS (US) | 2015-08-11 | — | — | US | disclosed |
| US-20140315915-A1 | DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315915-A1 | DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-10-23 | — | — | US | disclosed |
| US-8778945-B2 | Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778945-B2 | Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-07-15 | — | — | US | disclosed |
| US-20120040995-A1 | DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040995-A1 | DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2010091382-A1 | DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344452-A1 | PROCASPASE ACTIVATING COMPOUNDS | CASP3, CASP6, BAX | NPC1 3718/4885MEN1 3781/4885KMT2A 3165/4885 |
| US-20140315915-A1 | DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS | CASP3, CASP6, CASP14 | NPC1 4085/4885MEN1 3644/4885KMT2A 3466/4885 |
| US-20120040995-A1 | DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS | CASP3, CASP6, CASP14 | NPC1 4085/4885MEN1 3644/4885KMT2A 3466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.